Strategic Initiative

Slingshot members are tracking this corporate initiative:

Schrödinger (SDGR) Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb (BMY)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details The multi-year collaboration will combine Schrödinger’s leading physics-based computational platform and drug discovery capabilities with Bristol Myers Squibb's expertise in development and commercialization to advance small molecule therapeutics for targets in oncology, immunology, and neurological disorders. The collaboration includes two of Schrödinger’s early-stage programs and additional undisclosed targets. Schrödinger will be responsible for the discovery of development candidates for each of the targets under the collaboration. Bristol Myers Squibb will then be responsible for the development, manufacturing, and commercialization of the candidates.

Terms of the Collaboration
Under the terms of the agreement, Bristol Myers Squibb will pay Schrödinger $55 million upfront, and Schrödinger will also be eligible to receive up to $2.7 billion in preclinical, development, regulatory and sales-based milestone payments. Additionally, Schrödinger is entitled to receive royalties on net sales of each product commercialized by Bristol Myers Squibb.
Schrödinger has agreed to grant Bristol Myers Squibb exclusive worldwide rights to develop and commercialize the development candidates generated by the collaboration.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Nov 23, 2020
Projected Implementation:
Q4, 2020
Relevance Tracked Until:
Q1, 2021
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Drug Discovery, Oncology, Immunology, Neurological Disorders